Phase I, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects, Followed by a Genotypic Resistance Monitoring Study.

Trial Profile

Phase I, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects, Followed by a Genotypic Resistance Monitoring Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2011

At a glance

  • Drugs JTK 853 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top